Pelvic exenteration for primary carcinoma of the uterine cervix.
D000230:Adenocarcinoma / Q000401:mortality / Q000601:surgery*; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000601:surgery*; D005260:Female; D005767:Gastrointestinal Diseases / Q000453:epidemiology; D005831:Genital Diseases, Female / Q000453:epidemiology; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000601:surgery; D010385:Pelvic Exenteration; D011183:Postoperative Complications / Q000453:epidemiology; D011300:Preoperative Care; D011379:Prognosis; D012189:Retrospective Studies; D012509:Sarcoma / Q000401:mortality / Q000601:surgery*; D012771:Shock, Hemorrhagic / Q000150:complications; D012773:Shock, Surgical / Q000150:complications; D013530:Surgical Wound Infection / Q000453:epidemiology; D013997:Time Factors; D014570:Urologic Diseases / Q000453:epidemiology; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000601:surgery*
D000900:Anti-Bacterial Agents